{"id":"W4288987527","doi":"10.1016/j.esmoop.2022.100530","title":"Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Relay Therapeutics; Tessa Therapeutics; Aptose Biosciences; Banco Bilbao Vizcaya Argentaria; BeiGene; Jounce Therapeutics; Lilly Oncology; Bayer Fund; Mirati Therapeutics; Halozyme; Regeneron Pharmaceuticals; Boston Scientific Corporation; Fundación BBVA; F. Hoffmann-La Roche; AbbVie; Novartis; Celgene; Medtronic; Fundación Cellex; Les Laboratories Pierre Fabre; Meso Scale Diagnostics; Sanofi; Mersana Therapeutics; Merck; GlaxoSmithKline; Eli Lilly and Company; “la Caixa” Foundation; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Amgen; Boehringer Ingelheim; Pfizer; National Cancer Institute; Servier; Gilead Sciences; Taiho Pharmaceutical; Conquer Cancer Foundation","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Adverse effect; Immunogenicity; Oncology; Internal medicine; Cancer; Antibody; Response Evaluation Criteria in Solid Tumors; Pharmacology; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00232887,0.002752551,0.002564948,0.0007324786,0.0006158404,0.001396303,0.001232915,0.001644815,0.004365606],"category_scores_gemma":[0.0008795098,0.00085002,0.001204303,0.0005320888,0.001364356,0.001178497,0.0004582932,0.004125167,0.001170187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001696221,"about_ca_system_score_gemma":0.002739795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001388648,"about_ca_topic_score_gemma":0.003697264,"domain_scores_codex":[0.9992749,0.0003335719,0.00002434043,0.000116448,0.00007518503,0.0001756111],"domain_scores_gemma":[0.999121,0.0001177072,0.0001738933,0.00009051716,0.00006702396,0.0004297696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4599224,0.2147357,0.004966229,0.001297514,0.001242601,0.0004219814,0.0005582568,0.004896245,0.1835037,0.0008162105,0.0129805,0.1146585],"study_design_scores_gemma":[0.2817289,0.6919941,0.004668157,0.00003638122,0.0003005243,0.0003579394,0.0000555078,0.001439366,0.01439182,0.0003251479,0.004665833,0.00003627558],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814123,0.003226471,0.002086258,0.0006036568,0.0002353847,0.006505249,0.003279897,0.000335501,0.002315279],"genre_scores_gemma":[0.9740078,0.002850889,0.004725761,0.001093312,0.0002922635,0.005654898,0.005472478,0.000125333,0.005777332],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004365606,"threshold_uncertainty_score":0.01460439,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05214843498204853,"score_gpt":0.4088325772980611,"score_spread":0.3566841423160125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}